Study wrapper · #179
SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.
Editor's note
This is a study-design paper describing SURMOUNT-REAL UK, a planned 5-year, Phase 4, open-label pragmatic randomised trial, not a results report. It is worth logging precisely because of what it will test: effectiveness of tirzepatide added to standard care in UK primary care for around 3,000 adults with Class I obesity (BMI 30-34.9) and no diabetes, using linked electronic health records, with percent weight change at 24 months as the primary endpoint and time to onset of type 2 diabetes at 60 months as a key secondary. Pragmatic, open-label trials trade the internal rigour of blinded efficacy trials for external validity, real-world effectiveness under ordinary conditions, which complements the tightly controlled SURMOUNT efficacy programme. No outcomes exist yet; open-label design and reliance on routine records introduce measurement and behaviour caveats that only the eventual data will resolve. For readers, the signal here is that a real-world effectiveness and diabetes-onset question is being asked at population scale, not that any finding has landed.
Plain-language abstract
This paper describes the plan for a new trial, SURMOUNT-REAL UK; it does not report any results. The trial will test how well tirzepatide works in everyday practice when added to usual care for adults in Greater Manchester who have Class I obesity (BMI between 30 and 34.9) and do not have diabetes. About 3,000 people will be split evenly by chance into two groups: one gets tirzepatide plus standard care, the other gets standard care alone. Because it is 'pragmatic' and open-label, everyone knows which treatment they receive, and the study uses participants' linked NHS health records to follow outcomes under real-world conditions rather than in a tightly controlled setting. The main measure is the percent change in body weight after 24 months. A key secondary measure is how long it takes for type 2 diabetes to develop, tracked out to 60 months. The study will also look at obesity-related complications, quality of life, healthcare use, work productivity and sick leave. Its aim is to inform obesity treatment decisions, guidelines and health policy. Findings are not yet available. (ClinicalTrials.gov: NCT07247084.)